Status:
COMPLETED
A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Prostatic Neoplasms
Neoplasm Metastasis
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-base...
Eligibility Criteria
Inclusion
- diagnosis of prostate cancer
- receiving docetaxel-based chemotherapy at the CCI
- age 18 years or over
- approval of oncologist
- informed written consent
Exclusion
- life expectancy less than 6 months
- Karnofsky performance score less than 70
- contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
- unable to understand, read, write and speak English
- unable or unwilling to attend supervised exercise sessions 3 times weekly
- unable or unwilling to complete outcome assessments
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00271687
Start Date
February 1 2006
End Date
November 1 2007
Last Update
February 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2